Receptor Tyrosine Kinase Function As Molecular Target In Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$415,788.00
Summary
As molecular cell biologist and protein chemist my motivation for research is to tackle metastatic cancer, one of the principle health burdens of the 21 century. Over the next five years I will lead R&D programs with national and international collaborators that will generate new diagnostic approaches and insights in basic and translational research. These will allow us to develop anti-cancer drugs, which target several of the mechanisms that are active in metastatic cancers.
Defining The Role Of Microphthalmia-associated Transcription Factor (MITF) In Melanoma Heterogeneity By Real-time Cell Cycle Imaging
Funder
National Health and Medical Research Council
Funding Amount
$613,705.00
Summary
Metastatic melanoma is highly therapy-resistant. Modern targeted therapy is promising but suffers from rapid onset of drug resistance. Tumours consist of zones of fast growing cells next to zones of dormant cells. This tumour heterogeneity is one of the reasons for cancer drug resistance, as cells in different growth states respond differently to drugs. By understanding the causes of tumour heterogeneity we will set the basis for innovative clinical approaches against this devastating disease.
Molecular Pathways Mediating The Anti-tumour Activity Of WIF1
Funder
National Health and Medical Research Council
Funding Amount
$462,342.00
Summary
Osteosarcoma is the most common bone cancer. Treatment often entails aggressive surgery with intensive chemotherapy, although one third of those diagnosed will still die from this disease. We have found that the molecule WIF1 can suppress osteosarcoma growth. In this project we aim to identify genetic modifiers of WIF1, potential WIF1 interactors and define active domains of WIF1 for the development of more effective targeted therapeutics for osteosarcoma.
Aberrant Transcriptional Signalling In The Progression And Metastasis Of Melanoma.
Funder
National Health and Medical Research Council
Funding Amount
$353,033.00
Summary
There are currently no treatments that have any impact on decreasing mortality from metastatic melanoma. We have found 2 new variants in melanoma that may control the tumour growing and invading around the body. This study will examine the protein containing these changes with the aims of finding how they function differently, to identify their roles in the formation of melanoma, as well as to identify new targets for prevention and treatment of metastatic disease.
Role Of The Inositol Polyphosphate 4-phosphatase Type 2 In Human Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$611,032.00
Summary
Breast cancer is the most invasive cancer in females, affecting 1 in 9 women before the age of 85. Normally cells only divide when they receive a stimulus from a hormone or growth factor. The PI3K pathway responds to these stimuli and has been implicated in cancer when cells divide uncontrollably and invade surrounding tissue. We have identified a potential cancer suppressing gene, 4-ptase-2 that turns off the PI3K growth signals. We aim to characterize the role of 4-ptase-2 in breast cancer.
Breast cancer is the most frequent malignancy among women, with an estimated 1 million new cases per year worldwide. A family of enzymes known as protein tyrosine kinases (PTKs) are fundamental in the initiation and progression of tumour growth and they are frequently hyperactivated in breast cancer. This proposal will examine whether inactivation of the enzyme known as TCPTP contributes to PTK hyperactivation and tumorigenicity in breast cancer.
Identifying And Characterizing Genes That Regulate Breast Tumorigenesis And Metastasis
Funder
National Health and Medical Research Council
Summary
I am a breast cancer biologist. My research focuses on identifying the changes in normal cells that allow cancer to form, and identifying the changes in cancer cells that allows them to spread. To accomplish this, I have developed new methods using mouse models of breast cancer. My goal is to use these methods to further our understanding of the causes of breast cancer development and progression.
Regulation Of Innate Immunity And Tumour Progression By Activating Transcription Factor 3
Funder
National Health and Medical Research Council
Funding Amount
$473,469.00
Summary
Toll-like receptors (TLRs) play an essential role in innate immune responses and are involved in initiating tumourigenesis via inflammatory pathways. We have shown that the transcription factor ATF3 is a negative regulator of TLR signalling. We will study how modulation of the activity of ATF3 affects the inflammatory response and tumour progression. This will provide a molecular basis on which to design therapeutic reagents for the treatment of cancer.
Regulation Of ERK Driven Cell Proliferation By The Actin Cytoskeleton
Funder
National Health and Medical Research Council
Funding Amount
$920,972.00
Summary
The cells in your body respond to external signals and control their proliferation by transmitting signals from one part of the cell to another. This has usually been thought to involve the movement of signals through a liquid medium without the involvement of any machinery to control the movement. The project aims to test the role of the architecture of the cells in physically moving a growth signal from one place to another. We think that the architecture involved plays a key role in cancer.